Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Yarrow Bioscience, Inc.VYNE · Entity 6871 | CHIEF LEGAL OFFICER AND GC | July 23, 2026 | July 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Yarrow Bioscience, Inc.
Report date July 23, 2026 · Filed July 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 95,918 |
Reported balance
After 2026-07-23 transaction · row 1
1 source rowRow 1 · 2026-07-23 · Tax withholding · Disposed 22,516 · Balance 95,918 F1: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Foamix Pharmaceuticals Ltd.
Report date March 09, 2020 · Filed March 11, 2020
Section 16 reporting ended · disclosed 2020-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2020-03-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-03-09 · Disposition to issuer · Disposed 12,742 · Balance 85,490 F1: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2) F2: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement. Row 2 · 2020-03-09 · Disposition to issuer · Disposed 85,490 · Balance 0 F3: Represents Foamix restricted stock unit awards ("Foamix RSUs") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an "Adjusted RSU Award") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $6.35 · Expires 2028-02-27 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-03-09 · Disposition to issuer · Disposed 50,000 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F4: The ordinary shares underlying this option vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending March 31, 2022. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.77 · Expires 2029-01-01 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-03-09 · Disposition to issuer · Disposed 70,297 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F6: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2020 and 6.25% every three months thereafter) ending March 31, 2023. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $4.03 · Expires 2030-02-24 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-03-09 · Disposition to issuer · Disposed 96,365 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F7: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2)
F2: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement.
F3: Represents Foamix restricted stock unit awards ("Foamix RSUs") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an "Adjusted RSU Award") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR.
F4: The ordinary shares underlying this option vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending March 31, 2022.
F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options.
F6: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2020 and 6.25% every three months thereafter) ending March 31, 2023.
F7: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024.
Satsuma Pharmaceuticals, Inc.
Report date June 08, 2023 · Filed June 08, 2023
Section 16 reporting ended · disclosed 2023-06-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.48 | Direct | 0 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Disposition to issuer · Disposed 40,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.46 | Direct | 0 |
Reported balance
After 2023-06-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-08 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes.
F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 23, 2026 Filed Jul 24, 2026 21:00 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 22,516 | $0.90 | $20,210.36 |
DisclosureSEC source: 0001727809-26-000008 · form4-07242026_050703.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · CHIEF LEGAL OFFICER AND GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,918 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 30, 2026 Filed Jul 3, 2026 00:05 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 3,464 | $0.65 | $2,254.02 |
DisclosureSEC source: 0001727809-26-000006 · form4-07022026_080702.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · CHIEF LEGAL OFFICER AND GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,434 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:15 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 4,007 | $0.60 | $2,394.18 |
DisclosureSEC source: 0001727809-26-000004 · form4-04022026_040405.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · CHIEF LEGAL OFFICER AND GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,898 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 13:30 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 3,579 | $0.58 | $2,076.18 |
DisclosureSEC source: 0001727809-26-000002 · form4-01052026_080101.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · CHIEF LEGAL OFFICER AND GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,905 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 21:05 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 3,581 | $0.34 | $1,199.64 |
DisclosureSEC source: 0001727809-25-000003 · form4-10022025_051003.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · CHIEF LEGAL OFFICER AND GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,484 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:30 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 3,581 | $1.65 | $5,908.65 |
DisclosureSEC source: 0001415889-25-019057 · form4-07022025_040706.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · CHIEF LEGAL OFFICER AND GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,065 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:15 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantCommon Stock | 1,145 | $0.81 | $927.45 |
DisclosureSEC source: 0001415889-25-015383 · form4-06032025_040603.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · CHIEF LEGAL OFFICER AND GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,646 F1 · kind: These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2024 and ending on May 31, 2025 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's common stock on May 30, 2025 (the last trading day of the offering period). Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:15 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 8,828 | $1.58 | $13,948.24 |
DisclosureSEC source: 0001415889-25-009631 · form4-04022025_040410.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · CHIEF LEGAL OFFICER AND GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,501 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 21:15 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 230,000 | $0.00 Strike: $2.77 | $0.00 |
DisclosureSEC source: 0001415889-25-001924 · form4-01232025_040104.xml · derivative · entry 1 Harsch Mutya · CIK 0001727809 · CHIEF LEGAL OFFICER AND GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2035-01-20 F1 · derivative.exercise_date: The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on March 31, 2026 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 31, 2024 Filed Jan 2, 2025 22:45 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 4,697 | $3.35 | $15,734.95 |
DisclosureSEC source: 0001415889-25-000154 · form4-01022025_050103.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · CHIEF LEGAL OFFICER AND GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,329 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 20:15 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 105 | $1.88 | $197.40 |
DisclosureSEC source: 0001415889-24-024381 · form4-10022024_041004.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · CHIEF LEGAL OFFICER AND GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,026 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:15 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 143 | $1.92 | $274.56 |
DisclosureSEC source: 0001415889-24-019174 · form4-07032024_040711.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · CHIEF LEGAL OFFICER AND GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,131 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:04 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 161 | $3.08 | $495.88 |
DisclosureSEC source: 0001415889-24-010067 · form4-04032024_090429.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · CHIEF LEGAL OFFICER AND GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,274 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 22:20 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 161 | $2.28 | $367.08 |
DisclosureSEC source: 0001209191-24-000467 · doc4.xml · nonDerivative · entry 2 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,435 F3 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 22:20 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001209191-24-000467 · doc4.xml · derivative · entry 3 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2033-12-31 F4 · derivative.exercise_date: The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on March 31, 2025 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 22:20 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000467 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,596 F1 · shares: Grant to the Reporting Person of a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2 · shares: The shares underlying the RSU vest over a period of 4 years. 25% of the shares subject to the award will vest on March 31, 2025 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:09 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001209191-23-058817 · doc4.xml · derivative · entry 2 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2033-12-12 F3 · derivative.exercise_date: The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on December 31, 2024 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:09 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-058817 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,096 F1 · shares: Grant to the Reporting Person of a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2 · shares: The shares underlying the RSU vest over a period of 4 years. 25% of the shares subject to the award will vest on December 31, 2024 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:21 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 1,154 | $3.83 | $4,419.82 |
DisclosureSEC source: 0001209191-23-051944 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,596 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 20:32 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 157 | $4.10 | $643.70 |
DisclosureSEC source: 0001209191-23-041107 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,750 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 16:17 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0000899243-23-014864 · doc4.xml · derivative · entry 2 Harsch Mutya · CIK 0001727809 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F1 · derivative.exercise_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F1 · derivative.expiration_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 16:17 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Disposition to issuerStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0000899243-23-014864 · doc4.xml · derivative · entry 1 Harsch Mutya · CIK 0001727809 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F1 · derivative.exercise_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F1 · derivative.expiration_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:34 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantCommon Stock | 3,664 | $3.46 | $12,663.88 |
DisclosureSEC source: 0001209191-23-033802 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,907 F1 · shares: These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2022 and ending on May 31, 2023 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's common stock on December 1, 2022. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:03 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 478 | $3.08 | $1,472.24 |
DisclosureSEC source: 0001209191-23-022798 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,243 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 20:01 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | PurchaseCommon Stock | 10,000 | $2.50 | $25,000.00 |
DisclosureSEC source: 0001209191-23-020477 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,721 F1 · balance_after: On February 10, 2023, the Issuer effected a one-for-18 reverse split of its Common Stock. The number of securities reported reflects the reverse split. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 22:12 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 1,813 | $0.15 | $271.95 |
DisclosureSEC source: 0001209191-23-001111 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,144 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 21:04 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 1,813 | $0.22 | $404.30 |
DisclosureSEC source: 0001209191-22-052353 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,957 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 21:00 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 1,813 | $0.39 | $705.26 |
DisclosureSEC source: 0001209191-22-040783 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,770 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 17:36 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001567619-22-012471 · doc1.xml · derivative · entry 1 Harsch Mutya · CIK 0001727809 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-06-02 F1 · derivative.exercise_date: The option shall vest in full and become exercisable on the day immediately preceding the 2023 Annual Meeting. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:09 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 3,630 | $0.65 | $2,359.50 |
DisclosureSEC source: 0001209191-22-022526 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,583 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| March 17, 2022 Filed Mar 18, 2022 21:09 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Options · Derivative | 75,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-22-020065 · doc4.xml · derivative · entry 2 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-03-17 F2 · derivative.exercise_date: The awards vest over four years, 25% on March 31, 2023 and 6.25% every three months thereafter, ending on March 31, 2026. Read SEC document |
| March 17, 2022 Filed Mar 18, 2022 21:09 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-020065 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,213 F1 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:40 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 1,484 | $1.02 | $1,513.68 |
DisclosureSEC source: 0001209191-22-000855 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,213 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| October 11, 2021 Filed Oct 12, 2021 17:17 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $4.41 | $0.00 |
DisclosureSEC source: 0001567619-21-018223 · doc1.xml · derivative · entry 1 Harsch Mutya · CIK 0001727809 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-10-11 F1 · derivative.exercise_date: The award shall vest as to 1/36 of the shares subject to the award on each monthly anniversary from October 11, 2021, subject to continued service through each applicable vesting date Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 21:11 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 1,484 | $1.39 | $2,062.76 |
DisclosureSEC source: 0001209191-21-058516 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,697 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:34 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Options · Derivative | 60,860 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001209191-21-054834 · doc4.xml · derivative · entry 2 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,860 Underlying: Common Stock · 60,860 shares Expires 2031-09-02 F2 · derivative.exercise_date: 50% of the shares subject to the stock option award will vest on September 30, 2022, and the remaining 50% of the shares will vest thereafter in equal, quarterly installments, subject to the Reporting Person's continued service through the vesting date. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:34 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantCommon Stock | 60,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-054834 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,181 F1 · shares: Represents an award of restricted stock units, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc. 100% of the awards will vest on September 30, 2023, subject to the Reporting Person's continued service through the vesting date. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:36 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 3,551 | $3.51 | $12,464.01 |
DisclosureSEC source: 0001209191-21-044977 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,322 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 16:14 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 1,765 | $6.84 | $12,072.60 |
DisclosureSEC source: 0001209191-21-024409 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,873 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 21:38 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Options · Derivative | 68,162 | $0.00 Strike: $8.33 | $0.00 |
DisclosureSEC source: 0001209191-21-013813 · doc4.xml · derivative · entry 2 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,162 Underlying: Common Stock · 68,162 shares Expires 2031-02-22 F2 · derivative.exercise_date: The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 21:38 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantCommon Stock | 29,213 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-013813 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,638 F1 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc. F2 · shares: The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 21:32 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 1,822 | $1.58 | $2,878.76 |
DisclosureSEC source: 0001209191-21-001090 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,703 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 21:31 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantCommon Stock | 10,460 | $1.45 | $15,114.70 |
DisclosureSEC source: 0001209191-20-061175 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,525 F1 · shares: These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on April 1, 2020 and ending on November 30, 2020 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on November 30, 2020 (the last trading day of the offering period). The reporting person purchased the maximum number of shares permitted by the terms of the ESPP during the calendar year. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 20:31 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 1,822 | $1.66 | $3,024.52 |
DisclosureSEC source: 0001209191-20-053156 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,065 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:24 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Tax withholdingCommon Stock | 1,822 | $1.73 | $3,152.06 |
DisclosureSEC source: 0001209191-20-040303 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,887 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:53 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Options · Derivative | 150,000 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0001209191-20-028036 · doc4.xml · derivative · entry 2 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-05-06 F2 · derivative.exercise_date: The awards vest over four years, 25% on June 30, 2021 and 6.25% every three months thereafter, ending on June 30, 2024. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:53 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-028036 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,712 F1 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo Therapeutics Inc. F2 · shares: The awards vest over four years, 25% on June 30, 2021 and 6.25% every three months thereafter, ending on June 30, 2024. Read SEC document |
| April 06, 2020 Filed Apr 7, 2020 21:22 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Tax withholdingCommon Stock | 4,474 | $1.40 | $6,263.60 |
DisclosureSEC source: 0001209191-20-023805 · doc4.xml · nonDerivative · entry 3 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,712 F4 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 21:22 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 92,302 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-023805 · doc4.xml · nonDerivative · entry 2 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,186 F3 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo. F1 · price: As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2) F2 · price: (continued from footnote 1) awards that were received by the reporting person as a result of the foregoing. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 21:22 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 26,381 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-023805 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,884 F1 · price: As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2) F2 · price: (continued from footnote 1) awards that were received by the reporting person as a result of the foregoing. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.